Exelixis shares rose 2.5% this morning to a price of $44.21. The stock is still trading within range of its average target price of $45.0, and over the last 52 weeks, it has recorded a 21.3% performance. Analysts have given the Large-Cap Biotechnology stock target prices ranging from $30.0 to $60.0 dollars per share, with an average rating of buy.
The stock has an above average percentage of its shares sold short at 10.4%, and a short ratio of 6.37. The company's insiders own 2.19% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 97.6% of Exelixis's shares being owned by this investor type.
Institutions Invested in Exelixis
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Blackrock Inc. | 11% | 29,366,959 | $1,298,313,230 |
| 2025-09-30 | Vanguard Group Inc | 10% | 26,064,571 | $1,152,314,660 |
| 2025-09-30 | Farallon Capital Management LLC | 7% | 19,501,500 | $862,161,297 |
| 2025-09-30 | Renaissance Technologies, LLC | 6% | 15,459,266 | $683,454,135 |
| 2025-09-30 | State Street Corporation | 4% | 11,114,815 | $491,385,960 |
| 2025-09-30 | AQR Capital Management, LLC | 3% | 9,181,359 | $405,907,872 |
| 2025-09-30 | Fuller & Thaler Asset Management Inc. | 3% | 8,320,794 | $367,862,295 |
| 2025-09-30 | LSV Asset Management | 3% | 7,768,627 | $343,450,992 |
| 2025-09-30 | Geode Capital Management, LLC | 3% | 7,670,959 | $339,133,090 |
| 2025-09-30 | Invesco Ltd. | 2% | 5,960,525 | $263,514,804 |
Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Exelixis.
